TYROS BIOPHARMA

newsroom

We believe in helping women own their day

The new website for GYNALAC® tackles some of the issues, social stigmas, taboos, misconceptions and challenges women face when dealing with vaginal odor and other symptoms of Bacterial Vaginosis. It provides women with the essential information they should know on how to treat and prevent vaginal odour and other symptoms of Bacterial Vaginosis as well as helpful tips on how to deal with vaginal odor and symptoms of Bacterial Vaginosis.

The new website for GYNATROF® tackles some of the issues, social stigmas, taboos, misconceptions and challenges women face when dealing with intimate dryness and other symptoms of vulvovaginal atrophy. It arms women with essential information they should know to treat and prevent vaginal dryness and other symptoms of vaginal atrophy.

GYNALAC®, a novel treatment to help women overcome their recurrent Bacterial Vaginosis, has been reviewed and approved to be part of the new “Brand Recognition Program” recently introduced by the Society of Obstetricians and Gynaecologists of Canada (SOGC).

The SOGC Brand Recognition Program aims to assist Canadian consumers to make informed choices when selecting over-the-counter products. This program is designed for non-prescription/over-the-counter products that are found to safely and effectively promote female sexual and reproductive health.

Eligible products are required to have:
• Received Health Canada approval for sale in the Canadian market;
• Demonstrated reasonable evidence of safety and efficacy, and pose no undue harm;
• Substantiated packaging claims and a perceived low risk.

Products are independently and carefully reviewed by a panel of medical professionals. “GYNALAC® is manufactured in Canada and will be available without a prescription across Canada in the feminine hygiene sections at participating pharmacies, within the next few weeks. GYNALAC® is also immediately available online at amazon.ca” concluded Lee Alexander Sciortino, Vice-President of Commercial Operations.

GYNALAC®, a novel treatment to help women overcome their recurrent Bacterial Vaginosis, is now available in Canada.

Bacterial vaginosis is the most common lower genital tract disorder among women of reproductive age (pregnant and non-pregnant) and the most prevalent cause of vaginal discharge and malodour. It has been associated with a significant number of obstetric and gynaecologic complications, such as preterm labour and delivery, premature rupture of membranes, spontaneous abortion, chorioamnionitis, postpartum endometritis, post-Caesarean delivery wound infections, postsurgical infections, and subclinical pelvic inflammatory disease.

GYNALAC® is a double-acting vaginal gel, which contains a unique formulation of both lactic acid and sodium hyaluronate, and is clinically proven to treat acute episodes of Bacterial Vaginosis and prevent their recurrences. Lactic acid is naturally produced by friendly bacteria (Lactobacillus) in a woman’s vagina and is the cornerstone in the normal maintenance of the vaginal ecosystem by contributing to the reestablishment of the natural vaginal flora. Presence in adequate amounts ensures the maintenance of an acidic vaginal pH, where Lactobacilli (friendly bacteria) can adequately proliferate and correctly metabolize. Clinical evidence shows that a treatment course of lactic acid helps to relieve and prevent symptoms of BV, thereby bringing a natural protection against intimate irritation. Sodium hyaluronate is a compound that is also naturally produced by a woman’s body. Sodium hyaluronate has a long lasting moisturizing effect and promotes wound healing by enabling cells to retain moisture in the tissue. These two natural ingredients are delivered directly into the vagina where they can restore the natural flora and help protect against odor.

Anthony Gouvousis, president of Tyros Biopharma, explains that “Bacterial Vaginosis is the most common cause of vaginal infections and is about twice as common as Yeast infections. It is estimated that up to 29% of women in North America can be infected and can be found in up to 25% of pregnant women. This type of infection occurs when the healthy balance between the “good” and the “bad” bacteria in the vaginal ecosystem becomes disrupted due to various external or physiological risk factors. When the number of protective bacteria (Lactobacilli) decreases, “bad” bacteria (such as Gardnerella) overgrow and BV symptoms occur. Bacterial vaginosis is usually not dangerous, however if left untreated it can increase the risk for other medical problems, including post-operative infections and pregnancy related complications. ”

GYNALAC® is manufactured in Canada and will be available without a prescription across Canada in the feminine hygiene sections at participating pharmacies, within the next few weeks.

Tyros Biopharma is pleased to announce that GYNALAC®, a non-antibiotic treatment to relieve and prevent symptoms of Bacterial Vaginosis and non-specific vaginitis, is now available at all Jean Coutu locations across Quebec.

Jean Coutu is the largest retail pharmacy chain in Quebec, with more than 400 stores in the province. “We are very excited to welcome Jean Coutu as the newest member of our distribution network,” says Anthony Gouvoussis, President of Tyros Biopharma.

Tyros Biopharma is pleased to announce that GYNALAC®, a non-antibiotic treatment to relieve and prevent symptoms of Bacterial Vaginosis and non-specific vaginitis, is now available at all Shoppers Drug Mart/Pharmaprix locations across Canada.

Shoppers Drug Mart is the largest retail pharmacy chain in Canada, with more than 1,253 stores from coast to coast. “We are very excited to welcome Shoppers Drug Mart as the newest member of our distribution network,” says Lee Alexander Sciortino, Vice-President of Commercial Operations for Tyros Biopharma.

GYNALAC®, a novel treatment to help women overcome their recurrent Bacterial Vaginosis, is now approved in Canada.

Bacterial vaginosis is the most common lower genital tract disorder among women of reproductive age (pregnant and non-pregnant) and the most prevalent cause of vaginal discharge and malodour. It has been associated with a significant number of obstetric and gynaecologic complications, such as preterm labour and delivery, premature rupture of membranes, spontaneous abortion, chorioamnionitis, postpartum endometritis, post-Caesarean delivery wound infections, postsurgical infections, and subclinical pelvic inflammatory disease.

GYNALAC® is a double-acting vaginal gel, which contains a unique formulation of both lactic acid and sodium hyaluronate, and is clinically proven to treat acute episodes of Bacterial Vaginosis and prevent their recurrences. Lactic acid is naturally produced by friendly bacteria (Lactobacillus) in a woman’s vagina and is the cornerstone in the normal maintenance of the vaginal ecosystem by contributing to the reestablishment of the natural vaginal flora. Presence in adequate amounts ensures the maintenance of an acidic vaginal pH, where Lactobacilli (friendly bacteria) can adequately proliferate and correctly metabolize. Clinical evidence shows that a treatment course of lactic acid helps to relieve and prevent symptoms of BV, thereby bringing a natural protection against intimate irritation. Sodium hyaluronate is a compound that is also naturally produced by a woman’s body. Sodium hyaluronate has a long lasting moisturizing effect and promotes wound healing by enabling cells to retain moisture in the tissue. These two natural ingredients are delivered directly into the vagina where they can restore the natural flora and help protect against odor.

According to Lee Alexander Sciortino, Vice-President of Commercial Operations at Tyros Biopharma, “GYNALAC® not only provides a novel solution to treat acute episodes of Bacterial Vaginosis, but is also clinically proven, in prophylaxis, to prevent recurrences of Bacterial Vaginosis. Recurrence rates after antibiotic treatment in excess of 70% after 6 months have been described, even after successful antibiotic treatment. One possible explanation for the high rate of recurrence is that antibiotic treatment does not re-establish the protective lactobacilli following therapy. Developing a routine with GYNALAC® helps a woman maintain the natural vaginal pH balance and prevent these recurrences.”

GYNATROF®, a non-hormonal vaginal moisturizer indicated for the immediate relief of dryness, itching, burning & painful sexual activity, associated with vaginal atrophy, has been reviewed and approved to be part of the new “Brand Recognition Program” recently introduced by the Society of Obstetricians and Gynaecologists of Canada (SOGC).

The SOGC Brand Recognition Program aims to assist Canadian consumers to make informed choices when selecting over-the-counter products. This program is designed for non-prescription/over-the-counter products that are found to safely and effectively promote female sexual and reproductive health.

Eligible products are required to have:
• Received Health Canada approval for sale in the Canadian market.
• Demonstrated reasonable evidence of safety and efficacy, and pose no undue harm.
• Substantiated packaging claims and a perceived low risk.

Products are independently and carefully reviewed by a panel of medical professionals.

GYNATROF® is available without a prescription across Canada in the feminine hygiene sections at participating pharmacies.

Tyros Biopharma is pleased to announce that GYNATROF® , a non-hormonal gel for the treatment of vaginal atrophy, is now available at all Shoppers Drug Mart/Pharmaprix locations across Canada. Shoppers Drug Mart the largest retail pharmacy chain in Canada, with more than 1,253 stores from coast to coast. “We are very excited to welcome Shoppers Drug Mart as the newest member of our distribution network,” says Anthony Gouvoussis, President of Tyros Biopharma. “For the first time, GYNATROF® will be available to women nationwide to relieve and treat the many uncomfortable symptoms of vaginal atrophy.” In 2013, Jean Coutu and Brunet were the first two pharmacy chains in Canada to list GYNATROF® . In recent months, a number of other regional chains have come on board, including: ARP, Proxim, IDA, Guardian, Uniprix, Familiprix, Family Health Care and Medicine Shoppe. Gynatrof is also available nationwide at Costco Pharmacy and online at Well.ca.

Tyros Biopharma is pleased to announce that GYNATROF® , a non-hormonal gel for the treatment of vaginal atrophy is now available in Brunet pharmacies across Quebec. Brunet operates a network of close to 200 pharmaceutical establishments under the banners: Brunet, Brunet Plus, Brunet Clinique and Clini Plus.

Tyros Biopharma is pleased to announce that, GYNATROF® , a non-hormonal gel for the treatment of Vaginal Atrophy is now available in Jean Coutu pharmacies across Quebec. Jean Coutu is the first pharmacy chain in Canada to list GYNATROF® . The product will be available of the shelf in two formats: 15 ml and 50 ml.

Tyros Biopharma is pleased to announce that Health Canada has licensed their first product, GYNATROF®, a non-hormonal gel for the treatment of Vaginal Atrophy and the associated symptoms of dryness, itching, burning and painful sexual activity. GYNATROF® will be available for sale in Canada in July 2013.

Welcome to Tyrosbiopharma.com, our home on the web for all the latest news and hot topics in women’s health.

A new pharmaceutical company committed to changing the face of women’s health was launched today in Canada. Montreal-based Tyros Biopharma plans to provide therapeutic alternatives with proven results that address the limitations in most treatment options available to menopausal women today. Tyros is currently developing its product portfolio, and anticipates Health Canada approval of its first product by October 2012.